ArticleNature communications2018

Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer.

Jingyi Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.